Loading...

We've got a brand new version of Simply Wall St! Try it out

4Front Ventures

CNSX:CNNX
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CNNX
CNSX
CA$238M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Cannex Capital Holdings Inc., through its subsidiaries, leases real estate properties and sells supplies to cannabis cultivators, processors, and dispensaries in the United States and Canada. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • 4Front Ventures has significant price volatility in the past 3 months.
CNNX Share Price and Events
7 Day Returns
0%
CNSX:CNNX
2.4%
CA Pharmaceuticals
-1.4%
CA Market
1 Year Returns
40.4%
CNSX:CNNX
-1.3%
CA Pharmaceuticals
-3.5%
CA Market
CNNX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
4Front Ventures (CNNX) 0% -3.8% -18.3% 40.4% - -
CA Pharmaceuticals 2.4% -10.7% -27.7% -1.3% 403.9% 360%
CA Market -1.4% -1.9% -1.9% -3.5% 4.2% -0.8%
1 Year Return vs Industry and Market
  • CNNX outperformed the Pharmaceuticals industry which returned -1.3% over the past year.
  • CNNX outperformed the Market in Canada which returned -3.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

CNNX Value

 Is 4Front Ventures undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether 4Front Ventures is trading at an attractive price based on the cash flow it is expected to produce in the future. But as 4Front Ventures has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for 4Front Ventures. This is due to cash flow or dividend data being unavailable. The share price is CA$1.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 4Front Ventures's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 4Front Ventures's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:CNNX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in USD $-0.24
CNSX:CNNX Share Price ** CNSX (2019-07-31) in CAD CA$1.25
CNSX:CNNX Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.756 $0.94
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 17.49x
Canada Market PE Ratio Median Figure of 537 Publicly-Listed Companies 14.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 4Front Ventures.

CNSX:CNNX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:CNNX Share Price ÷ EPS (both in USD)

= 0.94 ÷ -0.24

-3.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 4Front Ventures is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • 4Front Ventures is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does 4Front Ventures's expected growth come at a high price?
Raw Data
CNSX:CNNX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
118.3%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.04x
Canada Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.05x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for 4Front Ventures, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on 4Front Ventures's assets?
Raw Data
CNSX:CNNX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in USD $-0.04
CNSX:CNNX Share Price * CNSX (2019-07-31) in CAD CA$1.25
CNSX:CNNX Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.756 $0.94
Canada Pharmaceuticals Industry PB Ratio Median Figure of 146 Publicly-Listed Pharmaceuticals Companies 2.23x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.45x
CNSX:CNNX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:CNNX Share Price ÷ Book Value per Share (both in USD)

= 0.94 ÷ -0.04

-22.19x

* Primary Listing of 4Front Ventures.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 4Front Ventures has negative assets, we can't compare the value of its assets to the CA Pharmaceuticals industry average.

Next steps:

  1. Take a look at 4Front Ventures's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through 4Front Ventures's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess 4Front Ventures's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. 4Front Ventures has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CNNX Future Performance

 How is 4Front Ventures expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
118.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is 4Front Ventures expected to grow at an attractive rate?
  • 4Front Ventures's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • 4Front Ventures's earnings growth is expected to exceed the Canada market average.
  • 4Front Ventures's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:CNNX Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:CNNX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 118.3%
CNSX:CNNX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 87.7%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.4%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.5%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:CNNX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:CNNX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-04-30 365 61 54 2
2020-04-30 232 34 26 3
CNSX:CNNX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-04-30 14 -1 -44
2018-04-30 12 4 -6
2017-09-30 6 3 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • 4Front Ventures's earnings are expected to grow significantly at over 20% yearly.
  • 4Front Ventures's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:CNNX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from 4Front Ventures Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CNNX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-04-30
2020-04-30
CNSX:CNNX Past Financials Data
Date (Data in USD Millions) EPS *
2019-04-30 -0.24
2018-04-30 -0.05
2017-09-30 -0.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if 4Front Ventures will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess 4Front Ventures's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
4Front Ventures has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CNNX Past Performance

  How has 4Front Ventures performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 4Front Ventures's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 4Front Ventures does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare 4Front Ventures's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare 4Front Ventures's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
4Front Ventures's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 4Front Ventures Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CNNX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 13.94 -43.62 11.40
2018-04-30 11.90 -6.34 8.85
2017-09-30 5.72 -2.09 0.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if 4Front Ventures has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if 4Front Ventures has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if 4Front Ventures improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess 4Front Ventures's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
4Front Ventures has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CNNX Health

 How is 4Front Ventures's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 4Front Ventures's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 4Front Ventures's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • 4Front Ventures's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of 4Front Ventures's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • 4Front Ventures has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 4Front Ventures Company Filings, last reported 3 months ago.

CNSX:CNNX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 -7.85 14.03 10.64
2018-04-30 31.03 7.43 11.86
2017-09-30 1.26 25.72 0.28
  • 4Front Ventures has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if 4Front Ventures's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • 4Front Ventures has sufficient cash runway for more than 3 years based on current free cash flow.
  • 4Front Ventures has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 111.3% each year.
X
Financial health checks
We assess 4Front Ventures's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 4Front Ventures has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CNNX Dividends

 What is 4Front Ventures's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 4Front Ventures dividends.
If you bought CA$2,000 of 4Front Ventures shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 4Front Ventures's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 4Front Ventures's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:CNNX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.9%
Canada Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:CNNX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-04-30
2020-04-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 4Front Ventures has not reported any payouts.
  • Unable to verify if 4Front Ventures's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 4Front Ventures's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 4Front Ventures has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess 4Front Ventures's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 4Front Ventures afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 4Front Ventures has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CNNX Management

 What is the CEO of 4Front Ventures's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anthony John Dutton
COMPENSATION $60,000
AGE 62
TENURE AS CEO 1.4 years
CEO Bio

Mr. Anthony John Guy Dutton is a Principal of Delu Corp. Mr. Dutton serves as the Chief Executive Officer of DELU Enterprises Ltd. He has been President at Arco Resources Corp. since January 2016 and served as Chief Executive Officer January 2016. Mr. Dutton served as a Vice President of Corporate Relations Special Projects at IBC Advanced Alloys Corp. from April 07, 2016 to October 31, 2016. He served as the Chief Executive Officer of IBC Advanced Alloys Corp. (formerly, International Beryllium Corporation) since May 2006 until April 07, 2016 and served as its President from September 15, 2007 to April 07, 2016. Since 2006, Mr. Dutton has been a Principal of Primary Capital Group, where he advises small to medium sized companies on corporate finance issues including working capital allocation and the management of a its funding requirements via the public and private capital markets. He serves as a Director of Business Development at Imara Energy Corp. Mr. Dutton is a seasoned business executive and entrepreneur with a successful track record as an early stage investor and business founder. He served as the President of IBC Advanced Alloys Corp. since May 2006 until July 17, 2007 and also served as its Secretary. Mr. Dutton served as the Chief Executive Officer, President and Chief Financial Officer of Green Park Capital Corp., since June 4, 2007 and its Secretary since June 13, 2007. His areas of expertise are corporate finance, business development and strategic management. He is regularly engaged in developing strategic and financial plans for early stage and high growth companies. Since 2006, he served as the Chief Executive Officer, Chief Financial Officer, President and Secretary of Janina Resources Limited. He served as Secretary at IBC Advanced Alloys Corp. From 2000 to 2003, he served as Director of Corporate Communications of XML Global Technologies Inc. From 2004 to 2006, he served as a Corporate Finance and Strategic Advisor for Curzon Capital Inc. Mr. Dutton was a Director of Josephine Mining Corp., since March 1, 2011. He has been a Director of Arco Resources Corp., since December 20, 2011. He has been an Independent Director of Trakopolis IoT Corp. since October 28, 2016. He serves as an Independent Director of JPY Holdings Ltd. He has been Director of 0903658 B.C. Ltd. (formerly Centric Energy Corp.) since September 25, 2009. He serves as Director of Imara Energy Corp. He served as a Director at IBC Advanced Alloys Corp. from May 12, 2006 to October 31, 2016. He served as a Director at War Eagle Mining Co. Inc., from March 20, 2009 to November 7, 2012. He served as a Director of Green Park Capital Corp. since June 4, 2007. He served as a Director of Janina Resources Ltd., From 2003 to 2004, he was a self-employed Strategic Business Consultant. Mr. Dutton holds a BA in Economics from the University of British Columbia, a Masters of Architecture from Dalhousie University and a Joint MBA from the Cranfield School of Management in the United Kingdom and Groupe ESC in Lyon, France.

CEO Compensation
  • Anthony John's compensation has increased whilst company is loss making.
  • Anthony John's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the 4Front Ventures management team in years:

1.1
Average Tenure
51
Average Age
  • The average tenure for the 4Front Ventures management team is less than 2 years, this suggests a new team.
Management Team

Anthony John Dutton

TITLE
CEO, President & Director
COMPENSATION
$60K
AGE
62
TENURE
1.4 yrs

Leo Gontmakher

TITLE
COO & Director
COMPENSATION
$656K
AGE
32
TENURE
1.4 yrs

Jerry Derevyanny

TITLE
Executive VP Corporate Development & Non-Independent Director
AGE
34

D. Lee

TITLE
Company Secretary
COMPENSATION
$438K

Greg Marshall

TITLE
COMPENSATION
$519K
AGE
53
TENURE
0.8 yrs

Dave Croom

TITLE
Chief Financial Officer
AGE
51
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the 4Front Ventures board of directors in years:

1.4
Average Tenure
34
Average Age
  • The average tenure for the 4Front Ventures board of directors is less than 3 years, this suggests a new board.
Board of Directors

Roman Tkachenko

TITLE
Chairman of the Board
COMPENSATION
$3K
AGE
34
TENURE
1.3 yrs

Anthony John Dutton

TITLE
CEO, President & Director
COMPENSATION
$60K
AGE
62
TENURE
1.4 yrs

Leo Gontmakher

TITLE
COO & Director
COMPENSATION
$656K
AGE
32
TENURE
1.4 yrs

Jerry Derevyanny

TITLE
Executive VP Corporate Development & Non-Independent Director
AGE
34
TENURE
1.4 yrs

Dmitriy Goykhman

TITLE
Independent Director
COMPENSATION
$8K
AGE
34
TENURE
1.4 yrs

Tom Peters

TITLE
Independent Director
COMPENSATION
$19K
AGE
52
TENURE
1.4 yrs

Ian Smith

TITLE
Member of Capital Markets Advisory
TENURE
1.3 yrs
Who owns this company?
Recent Open Market Insider Trading
  • More shares have been bought than sold by 4Front Ventures individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
18. Jul 19 Buy Leonid Gontmakher Individual 18. Jul 19 18. Jul 19 35,000 CA$1.20 CA$42,146
X
Management checks
We assess 4Front Ventures's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 4Front Ventures has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CNNX News

Simply Wall St News

Cannex Capital Holdings (CNSX:CNNX) Has Us Worried With Its Last Reported Debt Levels

See our latest analysis for Cannex Capital Holdings What Is Cannex Capital Holdings's Debt? … CNSX:CNNX Historical Debt, July 17th 2019 How Strong Is Cannex Capital Holdings's Balance Sheet? … Because it carries more debt than cash, we think it's worth watching Cannex Capital Holdings's balance sheet over time.

Simply Wall St -

Update: Cannex Capital Holdings (CNSX:CNNX) Stock Gained 30% In The Last Year

For example, the Cannex Capital Holdings Inc. … View our latest analysis for Cannex Capital Holdings. … Because Cannex Capital Holdings is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now.

Simply Wall St -

CNNX Company Info

Description

Cannex Capital Holdings Inc., through its subsidiaries, leases real estate properties and sells supplies to cannabis cultivators, processors, and dispensaries in the United States and Canada. It is involved in the provision of turn-key real estate with operational infrastructure; cannabis growing-related consulting services; purchasing agent services; and sale of packaging and other non-cannabis product inputs, such as soil, indoor lighting, and packaging. The company is headquartered in Vancouver, Canada.

Details
Name: 4Front Ventures Corp.
CNNX
Exchange: CNSX
Founded:
CA$238,102,683
190,482,147
Website: http://www.cannexcapital.com
Address: 4Front Ventures Corp.
1241 Alberni Street,
Vancouver,
British Columbia, V6E 4R4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX CNNX Common Shares Canadian National Stock Exchange CA CAD 14. Mar 2018
OTCPK CNXX.F Common Shares Pink Sheets LLC US USD 14. Mar 2018
Number of employees
Current staff
Staff numbers
0
4Front Ventures employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/07 00:51
End of day share price update: 2019/07/31 00:00
Last estimates confirmation: 2019/06/28
Last earnings filing: 2019/07/16
Last earnings reported: 2019/04/30
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.